Logo

ipilimumab

BMS's Immunotherapies, CAR T-Cell Therapies Report Double-Digit Growth in Q1
Premium

Opdivo sales increased 15 percent while revenue from cell therapies Breyanzi and Abecma also grew due to increased manufacturing capacity.

French Biotech EverImmune Enters Clinical Stage With Targeted Microbiome Therapy Oncobax AK
Premium

The firm is evaluating if an oral pill containing the bacteria Akkermansia can improve immunotherapy responses among lung and kidney cancer patients.

BMS Posts Strong Q4 Precision Oncology Products Sales
Premium

The company reported solid sales growth from its immunotherapy franchise and strong uptake of CAR T-cell therapies Abecma and Breyanzi.

Immunotherapy-Related Myocarditis Caused by Rogue T-Cell Attack, Study Finds
Premium

Research pinpointing the mechanism causing myocarditis in some patients on immune checkpoint inhibitors could lead to biomarker tests to identify those at risk.

Autoantibody Test Shows It Can Predict Toxicity, Recurrence in Melanoma Patients on Immunotherapy
Premium

NYU researchers want to commercialize an LDT based on data that shows an autoantibody signature has dual capabilities.

Oct 4, 2022

Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients
Premium

Sep 13, 2022

Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy
Premium

Sep 11, 2022

TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma?
Premium

Aug 26, 2022

Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label
Premium

Jul 27, 2022

BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles
Premium

Jul 6, 2022

Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials

May 16, 2022

BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial

Apr 29, 2022

Bristol Myers Squibb Reports Double-Digit Increase in Opdivo, Yervoy Sales in Q1

Apr 4, 2022

European Commission Approves Immunocore's T-Cell Receptor Therapy Kimmtrak in Uveal Melanoma

Mar 25, 2022

Southeastern Researchers Tackle Lung Cancer Race Disparities With Biobanking, Risk Scores
Premium

Mar 10, 2022

Microbiotica Advancing Bacterial Signature to Improve Immunotherapy Response, Patient Selection
Premium

Feb 22, 2022

Zenith, BMS Begin Trial of ZEN-3694, Dual Checkpoint Inhibitors in Solid Tumors

Feb 4, 2022

Bristol Myers Squibb Q4 Revenue Growth Supported by Opdivo, Yervoy Sales

Nov 24, 2021

Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients
Premium

Nov 4, 2021

BMS, Inspirna to Study Yervoy, RGX-104 Combination in Endometrial Cancer

Oct 25, 2021

TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers

Oct 1, 2021

UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response

Sep 21, 2021

Early ESMO Data Show Interferon Signature's Ability to Guide Neoadjuvant Melanoma Immunotherapy

Jul 28, 2021

Bristol Myers Squibb Q2 Revenues Grow 16 Percent

Jul 16, 2021

In Brief This Week: Strata Oncology, Ideaya Biosciences, Children's Cancer Institute Australia, BMS